SEphB4-HSA

DB14797InvestigationalProtein Based Therapies

SEphB4-HSA is under investigation in clinical trial NCT02495896 (Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors).

Mechanism: Pharmacologically active on Ephrin-B2
Curator reviewed
Also known as: RECOMBINANT EPHB4-HSA FUSION PROTEIN

Resolves to

Compound

UNIISO0RV2V6EJ

Targets

P52799EFNB2

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

14Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with SEphB4-HSA, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account